Moderna’s combined Covid-19 and flu vaccine matched the efficacy of single shots in late-stage trial results published on Monday, opening the door for the mRNA vaccine maker to seek approval for its third product.
週一公佈的後期試驗結果顯示，莫德納(Moderna)的新冠和流感聯合疫苗與單獨疫苗的效力相當，這意味著這家mRNA疫苗生產商能夠爲其第三款產品申請許可。
您已閱讀6%（289字），剩餘94%（4545字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。